POINT BIOPHARMA GLOBAL INC (PNT) Stock Analyst Ratings
USA - NASDAQ:PNT - US7305411099 - Common Stock
12.5 USD
+0.02 (+0.16%)
12.51 USD
+0.01 (+0.08%)
ChartMill assigns a Buy % Consensus number of 69% to PNT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 15.05. This target is 20.36% above the current price.
PNT was analyzed by 15 analysts. The buy percentage consensus is at 69. So analysts seem to be have mildly positive about PNT.
In the previous month the buy percentage consensus was at a similar level.
PNT was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-12-21 | Brookline Capital | Downgrade | Buy -> Hold |
| 2023-10-24 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-10-06 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2023-10-04 | JonesTrading | Downgrade | Buy -> Hold |
| 2023-10-04 | Truist Securities | Downgrade | Buy -> Hold |
| 2023-05-16 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2022-12-14 | Raymond James | Initiate | Outperform |
| 2022-11-30 | SVB Leerink | Initiate | Outperform |
| 2022-11-15 | Truist Securities | Maintains | Buy |
| 2022-10-11 | Oppenheimer | Initiate | Outperform |
| 2022-09-16 | Truist Securities | Initiate | Buy |
| 2022-09-14 | Berenberg | Initiate | Buy |
| 2022-09-07 | JonesTrading | Initiate | Buy |
| 2022-08-16 | Guggenheim | Initiate | Buy |
| 2022-07-06 | William Blair | Initiate | Outperform |
| 2022-05-26 | Jefferies | Upgrade | Hold -> Buy |
| 2021-12-17 | Mizuho | Initiate | Underperform |
| 2021-07-29 | Cowen & Co. | Initiate | Outperform |
| 2021-07-27 | Jefferies | Initiate | Hold |
| 2021-07-26 | Piper Sandler | Initiate | Overweight |
POINT BIOPHARMA GLOBAL INC / PNT FAQ
What is the average price target for POINT BIOPHARMA GLOBAL INC (PNT) stock?
15 analysts have analysed PNT and the average price target is 15.05 USD. This implies a price increase of 20.36% is expected in the next year compared to the current price of 12.5.
Can you provide the consensus rating for POINT BIOPHARMA GLOBAL INC stock?
The consensus rating for POINT BIOPHARMA GLOBAL INC (PNT) is 69.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.